16:32 , Jun 20, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Viral infection; polio Cell culture studies identified benzothiophene-based VP1 inhibitors that could help treat human rhinovirus (HRV) or poliovirus infections. Screening of a small molecule library, chemical synthesis of analogs of the screening hit,...
07:00 , Oct 15, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Phospholipase D2 (PLD2)

Infectious disease INDICATION: Sepsis Mouse studies suggest inhibiting PLD2 could help treat sepsis. In two mouse models of sepsis, PLD2 knockout or a tool compound that inhibited PLD2 decreased levels of proinflammatory cytokines and chemokines...
07:00 , Aug 27, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Phospholipase D1 (PLD1)

Cancer INDICATION: Colorectal cancer Mouse and patient sample studies suggest inhibiting PLD1 could help treat colorectal cancer. In colorectal cancer patients, levels of PLD1 mRNA were higher in tumors than in surrounding normal tissues and...
07:00 , Sep 25, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Inflammatory bowel disease (IBD) Salt-inducible kinase 1 (SIK1; SIK) In vitro studies suggest SIK inhibitors could help treat IBD. In mouse bone marrow-derived dendritic...
07:00 , Jul 21, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Inflammation; sepsis Nuclear receptor subfamily 0 group B member 2 (NR0B2; SHP) Mouse and cell culture studies suggest increasing SHP activity could help treat sepsis...